https://www.thebodypro.com/collection/hepatitis-c

Featured

Acid-Reducing Agents and HCV Treatment Img
Hepatitis C

Acid-Reducing Agents and HCV Treatment

It is possible that acid-reducing agents could reduce the absorption of ledipasvir in Harvoni and, therefore, its ability to help cure HCV infection.

Sofosbuvir + Velpatasvir (Epclusa) + Ribavirin for Retreatment Img
Hepatitis C

Sofosbuvir + Velpatasvir (Epclusa) + Ribavirin for Retreatment

In a clinical trial where Epclusa was used along with the broad-spectrum antiviral drug ribavirin, the combination was able to cure 91% of participants who needed retreatment after their previous regimen had failed.

Sofosbuvir + Velpatasvir (Epclusa) in HIV Coinfection Img
Hepatitis C

Sofosbuvir + Velpatasvir (Epclusa) in HIV Coinfection

In a study sponsored by Gilead Sciences called Astral-5, researchers tested the fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) in 106 people who were coinfected with hepatitis C virus (HCV) and HIV.

Sofosbuvir + Velpatasvir (Epclusa) -- Interactions With Other Medicines Img
Hepatitis C

Sofosbuvir + Velpatasvir (Epclusa) -- Interactions With Other Medicines

The fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) has been evaluated for possible and potential interactions with other drugs.

Looking Back at Liver Cancer Rates Among People Who Received Interferon Therapy Img
Hepatitis C

Looking Back at Liver Cancer Rates Among People Who Received Interferon Therapy

Researchers at the University of Toronto conducted an intensive review of 37 published studies in which interferon was used as treatment for HCV infection. Among participants who were cured, 3% subsequently developed liver cancer. Among participants ...

Barcelona: Reports of Unexpected Cases of Liver Cancer in People Undergoing Treatment With DAAs Img
Hepatitis C

Barcelona: Reports of Unexpected Cases of Liver Cancer in People Undergoing Treatment With DAAs

Doctors in Barcelona recently reported an unexpected increase in liver cancer recurrence in people who had been or who are being treated for chronic hepatitis C virus (HCV) infection with new potent all-oral medicines called direct acting antivirals ...

Bologna Researchers Find No Link Between DAAs and Liver Cancer Img
Hepatitis C

Bologna Researchers Find No Link Between DAAs and Liver Cancer

Spurred by reports from other cities, doctors in Bologna, Italy, have reviewed their database to assess possible risk factors for liver cancer development and recurrence in 344 participants who were treated for hepatitis C virus (HCV) infection with ...

What Is the Prevalence of Hepatitis C Among HIV-Positive Gay, Bi, Two-Spirit and Other Men Who Have Sex With Men? Img
Hepatitis C

What Is the Prevalence of Hepatitis C Among HIV-Positive Gay, Bi, Two-Spirit and Other Men Who Have Sex With Men?

There has been an increase in the sexual transmission of hepatitis C among gay, bi and other men who have sex with men (MSM) in high-income countries, particularly among HIV-positive men. A systematic review and meta-analysis estimated how high the p...

Are Hepatitis C RNA Tests Too Variable for Planning 8-Week Treatment Regimens? Img
Hepatitis C

Are Hepatitis C RNA Tests Too Variable for Planning 8-Week Treatment Regimens?

Pretreatment hepatitis C (HCV) RNA levels proved consistently higher with the TaqMan assay than the Abbott assay for patients with high initial HCV loads, according to a 740-sample analysis involving people with HCV genotype 1 infection.

Enhanced Liver Fibrosis Marker Predicts Death in HIV/HCV-Positive Women Img
Hepatitis C

Enhanced Liver Fibrosis Marker Predicts Death in HIV/HCV-Positive Women

Enhanced liver fibrosis (ELF), a serum marker, predicted death within one to three years for women living with HIV/HCV coinfection better than two other markers, in an analysis of 381 women. However, all three markers together did not improve the pre...